{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:40:30Z","timestamp":1787701230037,"version":"build-2784847793"},"reference-count":23,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.3892\/etm.2013.1261","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T09:45:52Z","timestamp":1376646352000},"page":"977-982","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients"],"prefix":"10.3892","volume":"6","author":[{"given":"CHENGCHENG","family":"FU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUAN","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XUE","family":"XIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUI","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHENGLI","family":"XUE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XIAO","family":"MA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZHENGMING","family":"JIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AINING","family":"SUN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUIYING","family":"QIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEPEI","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2013,8,16]]},"reference":[{"key":"key20180108131751_b1-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"New Engl J Med"},{"key":"key20180108131751_b2-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3816\/CLML.2010.n.080","article-title":"Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma","volume":"10","author":"Talamo","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20180108131751_b3-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials","volume":"16","author":"Myeloma Trialists\u2019 Collaborative group","year":"1998","journal-title":"J Clin Oncol"},{"key":"key20180108131751_b4-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-08-238196","article-title":"Hematopoietic stem cell transplantation for multiple myeloma beyond 2010","volume":"115","author":"Blad\u00e9","year":"2010","journal-title":"Blood"},{"key":"key20180108131751_b5-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.6004\/jnccn.2011.0095","article-title":"Multiple myeloma","volume":"9","author":"Anderson","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"key20180108131751_b6-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"key20180108131751_b7-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108131751_b8-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180108131751_b9-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"key20180108131751_b10-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMct0805626","article-title":"Autologous hematopoietic stem-cell transplantation for multiple myeloma","volume":"360","author":"Harousseau","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180108131751_b11-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"key":"key20180108131751_b12-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108131751_b13-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"issue":"Suppl 15","key":"key20180108131751_b14-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"A8014","DOI":"10.1200\/jco.2010.28.15_suppl.8014","article-title":"Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study","volume":"28","author":"Moreau","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108131751_b15-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"key20180108131751_b16-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"key20180108131751_b17-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"key20180108131751_b18-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","article-title":"The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma","volume":"143","author":"Niesvizky","year":"2008","journal-title":"Br J Haematol"},{"key":"key20180108131751_b19-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V110.11.3598.3598","article-title":"Relapsed \/refractory multiple myeloma treated with lenalidomide\/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response","volume":"110","author":"Harousseau","year":"2007","journal-title":"Blood"},{"key":"key20180108131751_b20-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","article-title":"Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2","volume":"140","author":"Pineda-Roman","year":"2008","journal-title":"Br J Haematol"},{"key":"key20180108131751_b21-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108131751_b22-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"key20180108131751_b23-etm-06-04-0977","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","article-title":"Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies","volume":"29","author":"Moreau","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2013.1261\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T02:59:28Z","timestamp":1596337168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2013.1261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,16]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,8,16]]},"published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.3892\/etm.2013.1261"],"URL":"https:\/\/doi.org\/10.3892\/etm.2013.1261","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,16]]}}}